IPI Asac Mexico is one of the oldest, most important and well-established subsidiaries within the Asacpharma Group. With more than twenty-five years of history, the company earned recognition from the specialist medical community due to the quality of its products. It has garnered support through various studies and trials that validate the efficacy and safety of their offerings, aiming to solidify their position as the optimal solution for allergy patients and those prone to recurrent infections.
Alejandro Martín serves as the general manager of the Mexican subsidiary, bringing with him a wealth of experience and a forward-thinking vision that will drive growth and innovation.
- You recently assumed the role of the new general manager of IPI ASAC MEXICO. How are you approaching this new challenge?
With great enthusiasm! As the subsidiary celebrates its 25th anniversary, it has demonstrated a strong focus on results throughout its tenure in Mexico. Upon my arrival, I found a highly motivated team, dedicated to the sales process and committed to achieving results.
The challenge is significant as we are in the process of redesigning our business structure to accelerate the pace of growth. Maintaining the processes that have proven successful while incorporating a new strategy represents a strengthening of teamwork and sets us on a path toward high performance. This entails continuous improvement towards a standard of excellence and high quality in administration, logistics and even in our relationship with doctors, aiming to be the best choice in immunotherapy for every doctor and patient who chooses us.
- How has the pharmaceutical industry in Mexico evolved in recent years?
As you know, the Mexican pharmaceutical sector is highly competitive and ranks as the third-leading sector in terms of productivity in Mexico. Following the recent COVID-19 pandemic, we have had to confront the development of new concepts, innovate processes and face adversities. In this regard, it is a sector that has experienced double-digit growth in terms of units as well as values. This growth has compelled us to refine our approaches and develop new strategies in communication, production and more efficient distribution channels, all aimed at enhancing quality of life for Mexican patients.
And what strategies does your laboratory employ to promote the research and development of new medications?
Asacpharma, or IpiAsac, as the subsidiary is known, has placed special emphasis on developing local research. We are currently undertaking various clinical research protocols in prominent public and private institutions. These efforts aim to confirm the efficacy of our products and to showcase the positive impact that can be achieved among Mexican people who have allergy illnesses, significantly enhancing their quality of life.
Our product portfolio is currently classified by specialisation areas: Immunotherapy for allergies, Bacterial Immunotherapy, Immunomodulators complemented with vitamins and other products that truly set the company apart in the sector.
Through process standardisation, our offerings are becoming the benchmark in the medical community due to their quality and efficacy, making a notable difference in patient well-being.
- In your view, what do you consider to be the main trends in the Mexican pharmaceutical market and how is your company adapting to them?
Undoubtedly, the biologics market shows promising signs in the industry. However, as I’ve mentioned before, the pandemic prompted the need for processes to enhance people’s immunity. From this perspective, Asacpharma has become a focal point, offering cutting-edge products in Mexico that focus on strengthening the immune system. Our products aim to prevent allergy crises, develop the body’s trained immunity and thereby improve quality of life for patients.
The regulatory landscape has become a competitive advantage for us, with our products having obtained health registrations, aligning with the increased demands of institutional regulations.
- Speaking of the immunotherapy business, what is the current market situation for allergenic and bacterial vaccines?
It is experiencing significant growth and new competitors have entered the scene. In today’s expanding market, focusing on fortifying the immune system places us in the right time and place. As I’ve mentioned, the allergy market has taken an upward trend, compelling us to maintain a continuous improvement process and be clear about consolidating a specialist laboratory with the products we can offer to doctors and patients in Mexico and around the world.
Today, one of our differentiators is having health registrations and analytical certificates, along with a long shelf life. The presentation of our products positions us as the preferred choice for doctors in areas with extreme heat.
While it’s true that we must be prepared for new regulatory requirements from hospitals and health authorities in Mexico, seeking new allergenic extracts with higher prevalence in Mexico will help us gain a larger market share.
- Could you provide an overview of technological advancements in the development of allergy and bacterial vaccines and how your laboratory stays at the forefront in this area?
In our case, proposing sublingual therapies places us in an innovative framework, simplifying treatment adherence with easy administration of allergens and bacterial components. As leaders in bacterial solutions, we have a device that is currently the most comprehensive and influences three major groups: recurrent infections, such as respiratory and urinary tract infections and, importantly, in the growing concept of trained immunity within the medical community. We are conducting research protocols with reputable institutions and opinion leaders to obtain clinically endorsed evidence that reinforces the adoption of Asacpharma products among Mexican patients.
- What are the most noteworthy clinical research projects related to immunotherapy that your laboratory is involved in and what are the expected results?
As I’ve mentioned before, we are conducting research protocols in prestigious public and private institutions due to their academic relevance and influence on results. For confidentiality reasons and to avoid biases in the outcomes, I cannot disclose the names of the institutions or participants. However, I can advance that the partial results so far are successful. Once concluded, we plan to present them at national and international forums and publish the results in indexed journals relevant to the specialisation areas our products focus on.
- What ongoing projects are in progress?
At Ipi Asac, our subsidiary in Mexico, we are undergoing a fascinating process of strategic re-engineering that has set our growth objectives in a five-year strategic plan. This allows us to have a short, medium and long-term vision, presenting ourselves differently and differentiating in the medical community. There are very positive aspects in the way things have been done over the past 25 years and, as expected, what has worked for us will remain. We will differentiate our promotion, presence at conferences, presentations and relationships with medical societies, consolidating our position as a specialist in allergies and pioneer in allergen and bacterial research in Mexico.
- What are your short and long-term expectations for IPI ASAC Mexico?
As expected, sustained growth for the subsidiary is in the short term. Our focus is on increasing presence in the medical community with a strong emphasis on allergists and immunologists. We are now expanding our medical visit panel to include paediatricians, gynaecologists, urologists and general practitioners. This will complete the circle of support and focus on those involved in allergenic and bacterial immunity processes.
Looking at the long term, we aim to be the leader laboratory in allergenic as well as bacterial immunity therapies, due to the quality of our products and processes, as well as excellence in executing our strategies. We aim to be recognised as leaders in the market segments we participate in.
We have various projects on the horizon for launching new products and re-launching existing ones. Through teamwork and our collective vision as a subsidiary, we aim to achieve our vision and solidify our position as a global company, a leader in immunological processes.
